ABL1 Cancer Research Results

ABL1, Tyrosine-protein kinase ABL1: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
ABL1 is a protein tyrosine kinase involved in cell differentiation, division and stress response.
ABL1 (Abelson murine leukemia viral oncogene homolog 1) is a gene that encodes a protein tyrosine kinase, which plays a crucial role in various cellular processes, including cell division, differentiation, and response to stress.
ABL1, its role as an oncogene is most prominently illustrated by the BCR-ABL fusion protein, which is formed through a chromosomal translocation between the ABL1 gene and the BCR gene.
High ABL1 Expression: In some cancers, high levels of ABL1 expression may correlate with poor prognosis, while in others, it may not have a significant impact.
Scientific Papers found: Click to Expand⟱
6591- DAS,    Dasatinib in solid tumors
- Review, Var, NA
Src↓, Dasatinib is an oral, potent adenosine triphosphate-competitive inhibitor of multiple tyrosine kinases including BCR-ABL, c-KIT, platelet-derived growth factor receptor, and Src family kinases (SFKs).
PDGF↓,
ABL1↓, One striking feature of dasatinib is its promiscuous nature as a kinase inhibitor.
BioAv↝, Maximum plasma concentrations (Cmax ) of dasatinib are observed 0.5 – 6 h after oral administration.
Half-Life↝, The overall mean terminal half-life of dasatinib is 3 – 5 h.
Dose↝, 67 patients were treated; the MTDs were 120 mg twice daily for the 5D2 and 70 mg twice daily for the CDD group.
eff↑, The recommended Phase II dose is capecitabine 1000 mg/m 2 plus dasatinib 100 mg daily.

6590- DAS,    Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
- in-vitro, Pca, NA
Src↓, The novel SFK/Abl inhibitor, dasatinib (BMS-354825), is a promising therapeutic agent with oral bioavailability.
ABL1↓,
BioAv↑,
TumCG↓, Dasatinib has been shown to inhibit growth of Bcr-Abl-dependent chronic myeloid leukemia xenografts in nude mice.
Dose↓, In this study, we show that dasatinib blocks the kinase activities of the SFKs, Lyn, and Src, in human prostate cancer cells at low nanomolar concentrations.
TumCA↓, Consistent with inhibition of these signaling pathways, dasatinib suppresses cell adhesion, migration, and invasion of prostate cancer cells at low nanomolar concentrations.
TumCMig↓,
TumCI↓,

6589- DAS,    Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells
- in-vitro, CLL, NA
Src↓, Dasatinib (BMS-354825) is a potent dual Abl/Src kinase inhibitor approved for clinical use in CML patients.
ABL1↓,

6588- DAS,    Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Src↓, Dasatinib (formerly BMS-354825) is a small-molecule, ATP-competitive inhibitor of SRC and ABL tyrosine kinases with potency in the low nanomolar range.
ABL1↓,


Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

ABL1↓, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Src↓, 4,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

PDGF↓, 1,   TumCA↓, 1,   TumCI↓, 1,   TumCMig↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,   Dose↓, 1,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ABL1, Tyrosine-protein kinase ABL1
4 Dasatinib/Phyrago
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page